The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.

Inclusion Criteria:

• Have a clinical diagnosis of uncontrolled Type 2 Diabetes based on the World Health Organization classification or other locally applicable diagnostic standards, and who intend to fast during Ramadan
• Have HbA1c ≥7% within 30 days prior to screening
• Are glucagon-like peptide-1 receptor agonist (GLP-1 RA) naïve
• Have had stable body weight self-reported change ≤5 kilograms (kg) during the 90 days prior to screening
• Have body mass index ≥25 kilograms per square meter (kg/m2) at screening

Exclusion Criteria:

• Have Type 1 Diabetes or gestational diabetes
• Have a history of chronic or acute pancreatitis
• Have acute or chronic hepatitis
• Have evidence of a significant, uncontrolled endocrine abnormality
• Have a history of an active or untreated malignancy
• Have New York Heart Association Functional Classification IV congestive heart failure
• Have been treated with insulin within two weeks prior to screening

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.